← Back to Screener
Elicio Therapeutics, Inc. Common Stock (ELTX)
Price$12.20
Favorite Metrics
Price vs S&P 500 (26W)19.32%
Price vs S&P 500 (4W)15.39%
Market Capitalization$249.27M
All Metrics
Book Value / Share (Quarterly)$0.09
P/TBV (Annual)1.15x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.08
Price vs S&P 500 (YTD)66.09%
Gross Margin (TTM)98.48%
Net Profit Margin (TTM)-81.45%
EPS (TTM)$-2.62
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-2.62
EPS (Annual)$-4.33
ROI (Annual)-309.46%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-1577.53%
Cash / Share (Quarterly)$1.04
ROA (Last FY)-184.54%
Revenue Growth TTM (YoY)-91.88%
EBITD / Share (TTM)$-2.55
Operating Margin (TTM)-83.03%
Cash Flow / Share (Annual)$-2.08
P/B Ratio152.36x
P/B Ratio (Quarterly)85.10x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-663.06x
ROA (TTM)-141.56%
EPS Incl Extra (Annual)$-4.33
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)2.29x
3-Month Avg Trading Volume0.13M
52-Week Price Return178.81%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.59
P/S Ratio (Annual)108.38x
Asset Turnover (Annual)0.04x
52-Week High$14.93
Operating Margin (5Y Avg)-1344.62%
EPS Excl Extra (Annual)$-4.33
CapEx CAGR (5Y)-16.74%
26-Week Price Return28.07%
Quick Ratio (Annual)2.29x
13-Week Price Return68.74%
Total Debt / Equity (Annual)5.75x
Current Ratio (Quarterly)2.38x
Enterprise Value$240.111
Asset Turnover (TTM)0.33x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1687.39%
Cash / Share (Annual)$1.04
3-Month Return Std Dev85.43%
Gross Margin (5Y Avg)80.96%
Net Income / Employee (TTM)$-1
ROE (Last FY)-309.46%
Net Interest Coverage (Annual)-71.54x
EPS Basic Excl Extra (Annual)$-4.33
Total Debt / Equity (Quarterly)5.75x
EPS Incl Extra (TTM)$-2.62
Receivables Turnover (Annual)5.71x
ROI (TTM)-354.47%
P/S Ratio (TTM)8.39x
Pretax Margin (5Y Avg)-1577.53%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$14.54
Price vs S&P 500 (52W)143.71%
Year-to-Date Return70.23%
5-Day Price Return25.00%
EPS Normalized (Annual)$-4.33
ROA (5Y Avg)-122.69%
Net Profit Margin (Annual)-1687.39%
Month-to-Date Return26.75%
Cash Flow / Share (TTM)$-7.66
EBITD / Share (Annual)$-4.31
Operating Margin (Annual)-1722.61%
LT Debt / Equity (Annual)5.75x
LT Debt / Equity (Quarterly)5.75x
EPS Basic Excl Extra (TTM)$-2.62
P/TBV (Quarterly)3.80x
P/B Ratio (Annual)85.10x
Pretax Margin (TTM)-81.45%
Book Value / Share (Annual)$0.09
Price vs S&P 500 (13W)65.88%
Beta1.34x
Revenue / Share (TTM)$0.00
ROE (TTM)-977.67%
52-Week Low$4.70
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. Common Stock | 8.39x | -91.88% | 98.48% | — | $12.20 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Elicio Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary Amphiphile (AMP) platform, which delivers treatments directly to lymph nodes. The company targets biologically validated but traditionally hard-to-drug cancer targets for patients with limited treatment options.